[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fXZkNOtVg3l1TTCqyxWQWUMVrtXkqgGZu1wxycsOy4wk":8,"$fBw0lQmFSK-xsP845GfK7GC2xGb-GV51jZntxghuCzFI":55,"$f-8b4CF0aq2937vGauHSWPzCoJUEZD_h4oWqC04hhbMk":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},74475,867263,[],"https://ystcdn.venuertc.com/medical/ystApp/0YbWrtsGnIVSTzEaDbtlD7CaJRSwuqG9.png","李会敏","临清市人民医院","老年病内科","住院医师",384,0,"肺癌IV期用药实用指南：关键安全细节全解 👨‍⚕️💊","","https://ystcdn.venuertc.com/venue/AI/a8ba7743-add2-44e8-b7b0-cdfd0d8cb62d.jpg","\u003Cdiv class=\"lungcancer-material-container\">\n\n  \u003Ch1 id=\"material_title\" class=\"lungcancer-material-title\">\n    肺癌IV期用药实用指南：关键安全细节全解 👨‍⚕️💊\n  \u003C/h1>\n\n  \u003Cdiv class=\"lungcancer-material-intro lungcancer-material-bg\">\n    \u003Cp>\n      多种药物常被应用于肺癌IV期的治疗，比如紫杉醇脂质体、卡铂、特瑞普利单抗、重组人血管内皮抑制素等。它们在药理机制、用法用量、不良反应以及相互作用方面各有不同。如果用药细节掌握不当，既可能降低疗效，也可能带来潜在风险。本文将系统介绍这几类药物的7大用药关键点，帮你快速学会用药技巧，更好保障安全和效果。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 1. 剂型与服用技巧 -->\n  \u003Csection class=\"lungcancer-material-section lungcancer-material-bg\" style=\"background-image: linear-gradient(to right, #f7fafc 0%, #eef6f6 100%);\">\n    \u003Ch2>01 剂型选择与服用技巧 💉\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        紫杉醇脂质体与卡铂、特瑞普利单抗、重组人血管内皮抑制素均为注射剂型。所有药物都需要在医院由专业医务人员按流程静脉滴注或静脉推注，严禁自行操作。\n      \u003C/li>\n      \u003Cli>\n        紫杉醇脂质体作为脂质体制剂，输注前必须充分摇匀，不可剧烈摇晃以避免起泡。正确做法：输液前一小时按医嘱预防过敏反应，必要时给予抗组胺药或激素预处理。\n      \u003C/li>\n      \u003Cli>\n        卡铂属于铂类抗肿瘤药，长时间静脉滴注更能减少肾毒性。正确做法：输注结束后应补足液体，防止肾脏损伤。医务人员会根据每位患者的情况调整滴注速度和总液体量。\n      \u003C/li>\n      \u003Cli>\n        特瑞普利单抗为单克隆抗体类药物，滴注速度必须缓慢，首剂使用时尤其需要关注不良反应。正确做法：输注期间严密监测体温、血压及异常症状。\n      \u003C/li>\n      \u003Cli>\n        重组人血管内皮抑制素的使用周期短，注射前需核对药品批号，有助于追溯药品质量，减少不良事件风险。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 2. 药物机制简述（不展开治疗效果/疾病） -->\n  \u003Csection class=\"lungcancer-material-section lungcancer-material-bg\" style=\"background-image: linear-gradient(90deg, #eef6f6 0%, #f4f7fa 100%);\">\n    \u003Ch2>02 药品作用机制一览 🔬\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>紫杉醇脂质体：\u003C/strong>通过稳定微管结构，阻止细胞分裂，从而干扰异常细胞的增殖（Wani, M.C. et al., 1971）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>卡铂：\u003C/strong>可与细胞DNA交联，阻断基因复制过程，使细胞无法继续生长（Rosenberg, B. et al., 1969）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特瑞普利单抗：\u003C/strong>通过抑制PD-1通路，让免疫细胞恢复识别异常细胞的能力，增强体内清除作用（Ribas, A. & Wolchok, J.D., 2018）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>重组人血管内皮抑制素：\u003C/strong>阻断血管生成信号，切断异常细胞的营养供应，从而发挥作用（Folkman, J., 1971）。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 3. 正确用法用量（不重复机制） -->\n  \u003Csection class=\"lungcancer-material-section lungcancer-material-bg\" style=\"background-image: linear-gradient(to right, #f7fafc 0%, #e8f1ff 100%);\">\n    \u003Ch2>03 标准用法与剂量调整 📅\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>紫杉醇脂质体：\u003C/strong>常规每三周一次，剂量按体表面积（mg/m\u003Csup>2\u003C/sup>）精准计算。临床实际调整以骨髓抑制或其他不良反应为依据，不建议在家自行调整频率或剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>卡铂：\u003C/strong>剂量多按\u003Cspan>Calvert公式\u003C/span>计算，需结合肾功能（肌酐清除率）；肾功能受损者需降低用药量或调整周期。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特瑞普利单抗：\u003C/strong>通常每2-3周一次，按体重或固定剂量静脉滴注。首次用药需严密观察，后续可视耐受性调整方案。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>重组人血管内皮抑制素：\u003C/strong>通常两周一次，不同制剂略有差异。必须严格按照医生制定的周期和剂量执行。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>正确做法：\u003C/span>所有药物务必当面核对药品标签和批次，严格核实剂量，并由有资质的专业人员操作。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"lungcancer-material-case\">\n      \u003Cstrong>真实用药经验：\u003C/strong>\n      \u003Cspan>有一位患者进行紫杉醇脂质体+卡铂治疗后，因无过敏反应且骨髓抑制轻微，方案维持不变。说明剂量调整依赖具体用药反应，不能自行参考其他人方案。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 4. 特殊人群用药要求（安全点突出） -->\n  \u003Csection class=\"lungcancer-material-section lungcancer-material-bg\" style=\"background-image: linear-gradient(90deg, #e8f1ff 0%, #eef6f6 100%);\">\n    \u003Ch2>04 特殊人群用药安全 ⚠️\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>肾功能不全者：\u003C/strong>卡铂需特别关注肾功能，剂量和周期按肌酐清除率灵活调整，避免肾损伤加重。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>老年人：\u003C/strong>使用免疫制剂和化疗药物时，因代谢和骨髓功能下降，须谨慎起始剂量，优先选择监测方案。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>孕妇及哺乳期：\u003C/strong>上述药物均被列为妊娠和哺乳期禁用，可能导致胎儿损害或通过乳汁影响婴儿。必须咨询医生，绝不可自行决策。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>儿童：\u003C/strong>这些药物通常未经儿童大规模临床验证，原则上禁用或仅在特殊情况下谨慎按体重调整。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"lungcancer-material-case\">\n      \u003Cspan>临床报道：一位高龄患者使用卡铂时调整剂量后，骨髓恢复良好，无明显不良反应。充分说明个体条件影响用药选择。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 5. 药物相互作用与组合使用 -->\n  \u003Csection class=\"lungcancer-material-section lungcancer-material-bg\" style=\"background-image: linear-gradient(to right, #f0faf5 0%, #f7fafc 100%);\">\n    \u003Ch2>05 药物相互作用与组合策略 💡\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>紫杉醇脂质体+卡铂：\u003C/strong>联合时有增强骨髓抑制风险。正确做法：用药当天、前后必须检测血象，必要时暂停或调整方案。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特瑞普利单抗联合：\u003C/strong>与化疗药组合能加强免疫应答，但易出现免疫相关不良反应。医务部门需按周详计划逐一评估副作用，不要自行叠加其他免疫药物。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>重组人血管内皮抑制素：\u003C/strong>与上述药物联合应用时会增强出血和蛋白尿风险。正确做法：用药期间定期尿检和凝血功能监测，发现异常及时上报。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>不能与：\u003C/span>强烈肝酶诱导剂、其他免疫抑制剂或近效化疗药物并用，否则可能影响疗效或增副作用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"lungcancer-material-case\">\n      \u003Cstrong>经验总结：\u003C/strong>\n      \u003Cspan>临床有过多药联合出现免疫反应加剧但血象无明显变化。合理监测是关键，不同药物很难用一套规则套用。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 6. 常见不良反应与应对方法 -->\n  \u003Csection class=\"lungcancer-material-section lungcancer-material-bg\" style=\"background-image: linear-gradient(90deg, #f9fafd 0%, #e8f1ff 100%);\">\n    \u003Ch2>06 常见不良反应及处理 🩺\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>紫杉醇脂质体：\u003C/strong>常见骨髓抑制、脱发，偶发过敏反应。出现发热、呼吸急促及时暂停输注，并分段处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>卡铂：\u003C/strong>敏感人群可出现肾毒性、恶心呕吐、听力损伤，如尿量显著减少或突发头晕应速报医生。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特瑞普利单抗：\u003C/strong>部分患者可出现皮疹、发热、免疫相关副作用。正确做法：出现严重症状及时终止治疗并接受专科干预。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>重组人血管内皮抑制素：\u003C/strong>蛋白尿、口腔黏膜炎、出血风险升高。检测尿蛋白升高或出血请主动联系医务人员，及时调整药物。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>数据参考：\u003C/span>说明书提示，紫杉醇脂质体的骨髓抑制发生率可达80%，卡铂肾毒性比例约25%。副作用重在早监测、早处理。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 7. 药品储存与失误处理 -->\n  \u003Csection class=\"lungcancer-material-section lungcancer-material-bg\" style=\"background-image: linear-gradient(to right, #eef6f6 0%, #f7fafc 100%);\">\n    \u003Ch2>07 储存方法及错服处理 ☘️\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>紫杉醇脂质体：\u003C/strong>需避光、2-8℃冷藏保存。开封后应于规定时限内用完，剩余药品按医院危化品处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>卡铂：\u003C/strong>保持避光、室温存放即可。开封后如未用完，不可再次保存，应直接交由医务人员妥善销毁。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特瑞普利单抗与重组人血管内皮抑制素：\u003C/strong>两者均需冷藏，防止温度过高导致失效。药品损坏或变色后禁止继续使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>漏服及过量：\u003C/span>漏服要第一时间报告医务人员，不可自行补剂或调整周期。如疑似过量，立即停药并送医急救。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 结尾总结 -->\n  \u003Cdiv class=\"lungcancer-material-summary lungcancer-material-bg\">\n    \u003Ch2>结语：安全用药是关键 🔒\u003C/h2>\n    \u003Cp>\n      紫杉醇脂质体、卡铂、特瑞普利单抗、重组人血管内皮抑制素在实际运用中，各有剂型、机制、用法及副作用的独特要求。真正确保疗效和安全，必须严格遵循医务团队的方案、重视药品标签、周期和不良反应监测。尤其要注意特殊人群、药物组合和储存细节。最后，遇到任何用药相关问题，优先选择与专业医师沟通，不擅自调整方案。合理、安全地用药，才能帮助每一位患者更好迈向康复之路。\n    \u003C/p>\n    \u003Cp>\n      如果正在进行上述药物治疗，请密切关注以上7项细节，只有全方位防护，才能远离风险，实现用药最大效益。🛡️\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 参考文献 -->\n  \u003Cdiv class=\"lungcancer-material-ref lungcancer-material-bg\">\n    \u003Ch2>参考文献\u003C/h2>\n    \u003Cul>\n      \u003Cli>Wani, M.C., Taylor, H.L., Wall, M.E., Coggon, P., & McPhail, A.T. (1971). Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. \u003Cem>Journal of the American Chemical Society\u003C/em>, 93(9), 2325-2327.\u003C/li>\n      \u003Cli>Rosenberg, B., Vancamp, L., Trosko, J.E., & Mansour, V.H. (1969). Platinum compounds: a new class of potent antitumor agents. \u003Cem>Nature\u003C/em>, 222, 385-386.\u003C/li>\n      \u003Cli>Ribas, A., & Wolchok, J.D. (2018). Cancer immunotherapy using checkpoint blockade. \u003Cem>Science\u003C/em>, 359(6382), 1350-1355.\u003C/li>\n      \u003Cli>Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. \u003Cem>New England Journal of Medicine\u003C/em>, 285(21), 1182–1186.\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.lungcancer-material-container {\n  font-family: 'Helvetica Neue', Helvetica, Arial, 'PingFang SC', 'Microsoft YaHei', sans-serif;\n  background: #fc;\n  padding: 38px 40px 24px 40px;\n  border-radius: 24px;\n  max-width: 880px;\n  margin: 32px auto;\n  box-shadow: 0 2px 16px rgba(120, 132, 154, 0.07), 0 0px 1px rgba(68, 77, 102, 0.11);\n  color: #163a52;\n}\n.lungcancer-material-title {\n  font-size: 34px;\n  color: #225588;\n  font-weight: 900;\n  text-align: left;\n  margin-bottom: 34px;\n  letter-spacing: 1px;\n}\n.lungcancer-material-intro {\n  background: #f7fafc;\n  border-radius: 12px;\n  padding: 18px 22px;\n  margin-bottom: 28px;\n  font-size: 18px;\n  border-left: 6px solid #cce8fd;\n  line-height: 1.8;\n}\n.lungcancer-material-section {\n  border-radius: 14px;\n  box-shadow: 0 4px 32px rgba(52, 86, 150, 0.05);\n  margin-bottom: 38px;\n  padding: 30px 26px 20px 26px;\n}\n.lungcancer-material-bg {\n  background-repeat: no-repeat;\n  background-size: cover;\n}\n.lungcancer-material-section h2 {\n  font-size: 25px;\n  color: #2867a5;\n  font-weight: 900;\n  margin-bottom: 19px;\n  padding-left: 6px;\n}\n.lungcancer-material-section ul {\n  margin: 0;\n  padding-left: 22px;\n  font-size: 18px;\n}\n.lungcancer-material-section ul li {\n  margin-bottom: 13px;\n  line-height: 1.7;\n  position: relative;\n}\n.lungcancer-material-section ul li span {\n  color: #166899;\n  font-weight: bold;\n}\n.lungcancer-material-case {\n  background: #e6effb;\n  margin: 19px 0 4px 0;\n  padding: 10px 13px;\n  border-radius: 7px;\n  color: #27497e;\n  font-size: 17px;\n  font-style: italic;\n  border-left: 4px solid #b6dafe;\n}\n.lungcancer-material-summary {\n  margin-top: 38px;\n  padding: 27px 26px;\n  border-radius: 14px;\n  font-size: 19px;\n  background: linear-gradient(90deg, #f7fafc 60%, #eef6f6 100%);\n  box-shadow: 0 2px 8px rgba(100, 134, 170, 0.04);\n  color: #1a3967;\n}\n.lungcancer-material-summary h2 {\n  font-size: 23px;\n  color: #256baa;\n  font-weight: 900;\n  margin-bottom: 13px;\n  padding-left: 2px;\n}\n.lungcancer-material-summary p {\n  margin-bottom: 14px;\n  line-height: 1.74;\n}\n.lungcancer-material-ref {\n  margin-top: 34px;\n  padding: 18px 22px;\n  background: linear-gradient(90deg, #eef6f6 0%, #f7fafc 100%);\n  border-radius: 10px;\n  font-size: 17px;\n  color: #418aca;\n  box-shadow: 0 1px 6px rgba(155, 180, 220, 0.07);\n}\n.lungcancer-material-ref h2 {\n  font-size: 20px;\n  color: #2679b3;\n  font-weight: 700;\n  margin-bottom: 11px;\n}\n.lungcancer-material-ref ul {\n  padding-left: 21px;\n  margin: 0;\n}\n.lungcancer-material-ref li {\n  margin-bottom: 10px;\n  line-height: 1.7;\n  font-size: 16px;\n}\n\n@media (max-width: 980px) {\n  .lungcancer-material-container {\n    padding: 24px 10px;\n    max-width: 100%;\n    margin: 16px;\n  }\n  .lungcancer-material-title {\n    font-size: 26px;\n  }\n  .lungcancer-material-section,\n  .lungcancer-material-summary {\n    padding: 16px 10px 14px 10px;\n  }\n  .lungcancer-material-ref {\n    padding: 10px 7px;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"lungcancer-material-container\">\n\n  \u003Ch1 id=\"material_title\" class=\"lungcancer-material-ti",415,"2025-11-28 00:45:32","肺癌, IV期, 用药安全, 紫杉醇脂质体, 卡铂, 特瑞普利单抗, 不良反应, 医疗指南","探索肺癌IV期的重要用药指南，了解紫杉醇脂质体、卡铂等药物的使用细节和安全措施，帮助患者提升治疗效果和安全性。","2025-12-15 16:46:49",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]